Biosimilar Granulocyte Colony-Stimulating Factor Uptakes in the EU-5 Markets: A Descriptive Analysis
Bocquet, François; Paubel, Pascal; Fusier, Isabelle; Cordonnier, Anne-Laure; Le Pen, Claude; Sinègre, Martine (2014), Biosimilar Granulocyte Colony-Stimulating Factor Uptakes in the EU-5 Markets: A Descriptive Analysis, Applied Health Economics and Health Policy, 12, 3, p. 315-326. 10.1007/s40258-014-0087-8
Type
Article accepté pour publication ou publiéDate
2014Journal name
Applied Health Economics and Health PolicyVolume
12Number
3Publisher
Springer
Pages
315-326
Publication identifier
Metadata
Show full item recordAuthor(s)
Bocquet, FrançoisInstitut Droit et Santé [IDS - U1145]
Paubel, Pascal
Institut Droit et Santé [IDS - U1145]
Fusier, Isabelle
Cordonnier, Anne-Laure
Le Pen, Claude
Sinègre, Martine
Abstract (EN)
Background Biosimilars are copies of biological reference medicines. Unlike generics (copies of chemical molecules), biologics are complex, expensive and complicated to produce. The knowledge of the factors affecting the competition following patent expiry for biologics remains limited. Objectives The aims of this study were to analyse the EU-5 Granulocyte-Colon Stimulating Factor (G-CSF) markets and to determine the factors affecting the G-CSF biosimilar uptakes, particularly that of biosimilar prices relative to originators. Methods Data on medicine volumes, values, and ex-manufacturer prices for all G-CSF categories were provided by IMS Health. Volumes were calculated in defined daily doses (DDD) and prices in Euros per DDD. In the EU-5 countries, there is 5 years of experience with biosimilar G-CSFs (2007–2011). Results Two G-CSF market profiles exist: (1) countries with a high retail market distribution, which are the largest G-CSF markets with low global G-CSF biosimilar uptakes (5.4 % in France and 8.5 % in Germany in 2011); and (2) countries with a dominant hospital channel, which are the smallest markets with higher G-CSF biosimilar uptakes (12.4 % in Spain and 20.4 % in the UK). The more the decisions are decentralized, the more their uptakes are high. The price difference between G-CSF biosimilars and their reference plays a marginal role at a global level (price differences of +13.3 % in the UK and −20.4 % in France). Conclusion The competition with G-CSF biosimilars varies significantly between EU-5 countries, probably because of G-CSF distribution channel differences. Currently, this competition is not mainly based on prices, but on local political options to stimulate tendering between them and recently branded second- or third-generation products.Subjects / Keywords
Health Economics; Pharmacoeconomics and Health Outcomes; Public Health; Quality of Life ResearchRelated items
Showing items related by title and author.
-
Bocquet, François; Paubel, Pascal; Fusier, Isabelle; Cordonnier, Anne-Laure; Le Pen, Claude; Sinègre, Martine (2014) Article accepté pour publication ou publié
-
Fusier, Isabelle; Cordonnier, Anne-Laure; Paubel, Pascal; Bocquet, François; Le Pen, Claude (2013) Article accepté pour publication ou publié
-
Bocquet, François; Paubel, Pascal; Fusier, Isabelle; Cordonnier, Anne-Laure; Sinègre, Martine; Le Pen, Claude (2015) Article accepté pour publication ou publié
-
Degrassat-Théas, Albane; Paubel, Pascal; Parent de Curzon, Olivier; Le Pen, Claude; Sinègre, Martine (2013) Article accepté pour publication ou publié
-
Le Pen, Claude; Parent de Curzon, Olivier; Paubel, Pascal; Sinègre, Martine; Degrassat-Théas, Albane (2011) Article accepté pour publication ou publié